NDA 219868 · Azurity
Ferabright
Ferumoxytol · Intravenous
NovelOrphanLast checked: Nov 19, 2026Latest source record: Oct 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 16, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
97
20 Phase 3, 15 recruiting
FAERS reports
239
178 serious, 20 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS AND OTHER SERIOUS HYPERSENSITIVITY REACTIONS Fatal and serious hypersensitivity reactions, including anaphylaxis, have occurred in patients receiving ferumoxytol products that contain the same active ingredient as FERABRIGHT. Initial signs may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest. Hypersensitivity reactions have occurred even in patients who previously tolerated ferumoxytol. Only administer FERABRIGHT as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following FERABRIGHT infusion including monitoring of blood pressure and pulse during and after FERABRIGHT administration [see Warnings and...
What it is approved for
From the label in effect Oct 14, 2025.
FERABRIGHT is indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. FERABRIGHT is an iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.
Mechanism: Ferumoxytol is a superparamagnetic iron oxide coated with a carbohydrate shell that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues on T1-weighted MRI. Disruption of the blood-brain barrier allows distribution of ferumoxytol into lesions such as neoplasms. Since extravasation of the large ferumoxytol molecules is slow, parenchymal enhancement is seen in the delayed phase, approximately 24 hours post-administration of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2025 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelOrphanLetterLabel
2 products under this application
- FERABRIGHT · FERUMOXYTOL EQ 510MG IRON/17ML (EQ 30MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription
- FERABRIGHT · FERUMOXYTOL EQ 300MG IRON/10ML (EQ 30MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferumoxytol" as an intervention, any sponsor and status, largest first.
- A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT02694978 · 2,014 participants · Start Feb 29, 2016 · Primary completion Jan 16, 2017
Drug: Ferumoxytol; FCM · For: Iron Deficiency Anemia
Sites: Huntsville, Alabama; Tucson, Arizona; Anaheim, California · 127 sites in all
- A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114139 · 812 participants · Start Jun 19, 2010 · Primary completion Feb 27, 2012
Drug: Ferumoxytol · For: Iron Deficiency Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 182 sites in all
- A Crossover Safety Study of Ferumoxytol Versus PlaceboPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255450 · 750 participants · Start Jan 2005
Drug: ferumoxytol or placebo · For: Anemia
Sites: Mobile, Alabama; Phoenix, Arizona; Mountain View, California · 41 sites in all
- A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114217 · 634 participants · Start Jul 27, 2010 · Primary completion Sep 24, 2012
Drug: Ferumoxytol · For: Iron Deficiency Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 140 sites in all
- A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114204 · 605 participants · Start Aug 10, 2010 · Primary completion Nov 9, 2011
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia
Sites: Adelaide, Australia; Ballarat, Australia; Concord, Australia · 96 sites in all
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255437 · 304 participants · Start Jun 2004
Drug: ferumoxytol or oral iron · For: Anemia
Sites: Phoenix, Arizona; Tempe, Arizona; New Haven, Connecticut · 13 sites in all
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255424 · 304 participants · Start May 2004
Drug: ferumoxytol or oral iron · For: Anemia
Sites: Encino, California; Riverside, California; Tarzana, California · 19 sites in all
- Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on HemodialysisPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01227616 · 296 participants · Start Aug 2013 · Primary completion Feb 2016
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia Treatment; Chronic Kidney Disease(CKD)
Sites: Pine Bluff, Arkansas; Azusa, California; Beverly Hills, California · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea66
- infusion related reaction65
- nausea33
- anaphylactic reaction28
- back pain22
- vomiting22
- dizziness20
- chest discomfort19
- flushing19
- hypotension17
- chest pain13
- hypertension13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 12 |
| 2019 | 15 |
| 2020 | 13 |
| 2021 | 24 |
| 2022 | 22 |
| 2023 | 16 |
| 2024 | 25 |
| 2025 | 37 |
| 2026 | 32 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy.
Nicholson L, Axon E, Daru J, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- Intravenous Ferumoxytol Compared With Oral Ferrous Sulfate for Iron Deficiency Anemia in Pregnancy: A Randomized Controlled Trial.
Igbinosa II, Leonard SA, Iwekaogwu I, et al. · Obstet Gynecol 2026 · Randomized Controlled Trial, Comparative Study
- Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Ravi H, Arias-Lorza AM, Costello JR, et al. · Radiol Imaging Cancer 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Ferumoxytol for treating iron deficiency anemia in CKD.
Spinowitz BS, Kausz AT, Baptista J, et al. · J Am Soc Nephrol 2008 · Clinical Trial, Phase III, Randomized Controlled Trial
- Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.
Muehe A, Nejadnik H, Muehe H, et al. · Biointerphases 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging.
Khan S, Amin FM, Fliedner FP, et al. · Cephalalgia 2019 · Clinical Trial
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.